Abstract: A production method for an MP whey is provided, that enables preparation of both of a high GMP-content composition and a usable MP whey from an ordinary MP whey. The problems can be solved by a production method for a glycomacropeptide-containing composition, that includes a step of acquiring a solution containing glycomacropeptide, that includes a glycomacropeptide content of 10% by weight or higher in the protein total amount by condensing and/or applying diafiltration to a microparticulated whey solution.

Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.

Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, which

Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, which

Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.

Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.

Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human ?9 integrin in their pathogenesis, which uses the antibody.

Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.

Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.

Abstract: The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.

Abstract: The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.

Abstract: A holding unit holds a plurality of types of white balance adjustment color data with respect to colors of the plurality of projection surfaces. A projection control unit causes a projection unit to simultaneously project patterns having a plurality of colors based on the plurality of types of held color data, upon dividing the patterns into areas configured to be selected for each pattern. A selection control unit causes a designation unit to select a pattern which is whitest from the patterns having the plurality of projected colors. When a given pattern is selected from the patterns having the plurality of colors projected, a color data acquiring unit acquires color data corresponding to the selected pattern from the plurality of types of held color data. A color correction unit performs color correction of an image to be projected.

Abstract: A holding unit holds a plurality of types of white balance adjustment color data with respect to colors of the plurality of projection surfaces. A projection control unit causes a projection unit to simultaneously project patterns having a plurality of colors based on the plurality of types of held color data, upon dividing the patterns into areas configured to be selected for each pattern. A selection control unit causes a designation unit to select a pattern which is whitest from the patterns having the plurality of projected colors. When a given pattern is selected from the patterns having the plurality of colors projected, a color data acquiring unit acquires color data corresponding to the selected pattern from the plurality of types of held color data. A color correction unit performs color correction of an image to be projected.

Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.

Abstract: A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditions caused by gelatinase and/or collagenase, and/or inflammatory diseases concerned with gelatinase; such as arthritis (e.g., osteoarthritis, rheumatoid arthritis, etc.) cerebral diseases (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastriculceration, etc.), abnormal wound healing, periodontal diseases, bone diseases (e.g., Paget's diseases, osteoporosis. etc.), tumor growth, tumor metastasis or invasion, HIV-infection, decubitus, decubitis ulcer, restenosis, epidermolysis bullosa, sepsis, septic shock, neoplasm, psoriasis, neovascularization and multiple sclerosis.

Abstract: Present invention is relating to a new use of a compound possessing an inhibitory activity on the production of nitric oxide, for increasing an effect caused by IL-2 inhibitor.

Abstract: Methods for increasing graft survival time comprising administering the combination of a compound that inhibits the production of nitric oxide and a compound that is a tricyclic macrolide, such as tacrolimus.

Abstract: An improved catalyst suitable for use in the production of an unsaturated carboxylic acid by the catalytic vapor phase oxidation of an unsaturated aldehyde is provided. In this catalyst, a heat-resistant inorganic substance, such as alumina, silica-alumina and silicon carbide, having a particle diameter of 3 through 10 mm, an apparent porosity of 35 through 60%, a water absorption of 20 through 50%, an average pore diameter of not less than 40 microns, a specific surface area of not more than 2 m.sup.2 /g and a bulk specific gravity of 1.5 through 2.0 is used for supporting a composition containing molybdenum, phosphorus, vanadium and the alkali metals. The use of the above-mentioned carrier results in the advantages that the unsaturated carboxylic acid, such as methacrylic acid, can be selectively produced from the unsaturated aldehyde at a high yield and that the mechanical strength of the catalyst is remarkably improved.

Abstract: Methacrolein is catalytically oxidized into methacrylic acid in the vapor phase at a temperature of 200.degree. to 450.degree. C. The catalyst used is comprised of molybdenum, phosphorus, potassium and/or cesium, vanadium, silver and/or tellurium, and oxygen, and represented by the formula:Mo.sub.12 P.sub.a A.sub.b V.sub.c X.sub.d O.sub.ewherein A is K and/or Cs and X is Ag and/or Te, and a=0.5-5, b=0.1-4, c=0.05-3, d=0.001-2 and e is a positive number required by the valence states of the other elements present.

Abstract: Unsaturated hydrocarbons having 4 to 6 carbon atoms are catalytically oxidized into maleic anhydride by using a catalyst, which consists essentially of oxides of (A) vanadium, (B) phosphorus, (C) titanium and (D) optionally at least one element selected from sodium, calcium, magnesium, iron, zirconium, boron, manganese, silver and molybdenum in the atomic ratios defined by the following formulaVP.sub.a Ti.sub.b X.sub.c O.sub.dwherein X is the element (D) set forth above and a=1.0 to 5.0, b=2.0 to 12.0 and c=0 to 1.0, and which catalyst is prepared by calcining a mixture of a vanadium-containing compound and titanium dioxide at a temperature of 650.degree. C. to 1,500.degree. C., incorporating into the mixture a phosphorus-containing compound and optionally the element "X"-containing compound and, then, heating the resulting mixture.